California Stem Cell Agency Exaggerated Its Role in Funding Key Research
Posted on: Wednesday, 16 April 2008, 18:00 CDT
SANTA MONICA, Calif., April 16 /PRNewswire-USNewswire/ -- California's stem cell agency overstated and hyped the importance of its funding in enabling clinical trials for a drug to treat a severe blood disorder, Consumer Watchdog said today, seriously undercutting the agency's credibility and alienating those who support publicly funded stem cell research.
Last week the California Institute For Regenerative Medicine (CIRM) issued a news release titled "First Clinical Trial Begins for a Therapy Enabled By CIRM Funding." The announcement even drew a comment from Gov. Arnold Schwarzenegger, who issued a release saying CIRM funding led to the discovery. He added, "I am proud of our state's commitment to stem cell research, which delivers the best promise in finding treatments for deadly and debilitating diseases."
A report on today's California Stem Cell Report published by David Jensen makes clear how little CIRM funding was actually involved in the research by a team led by UCSD's Catriona Jamieson.
"There is important scientific work here that led quickly to an important clinical trial," said John M. Simpson, director of Consumer Watchdog's Stem Cell Project. "But the fact is that CIRM is jumping on the bandwagon claiming credit for contributions that were at best rather trivial."
The initial CIRM news release about the clinical trial said that Jamieson was funded by a stem cell SEED grant that was approved in February 2007. That grant was given to fund the derivation of cancer-causing stem cells from human embryonic stem cells. The research that led to the clinical trial did not involve human embryonic stem cells at all.
Moreover, according to the official notice of grant award, the time period for the CIRM funded grant of $613,305 was from Aug. 1, 2007- July 31, 2009. The university officially signed off on the grant on Aug. 31, 2007. The paper outlining the research findings was submitted to "Cancer Cell" on Sept. 19, 2007.
Read the notice of grant award here: http://www.consumerwatchdog.org/resources/Noticeofgrant.pdf
"CIRM is too eager to claim immediate results," said Simpson. "Certainly we'll see great benefit as the result of stem cell research, but this political manipulation and hype does a tremendous disservice to all who believe in the value of this research."
After Jensen asked questions about the CIRM release, the agency modified the version posted on its website to note that an earlier CIRM training grant had gone to pay the salary of a post doctoral researcher in Jamieson's laboratory.
"Stem cell agency officials repeatedly say, 'It's all about the science,'" said Simpson. "If only that were true. More often than not -- as in this case -- it's all about appearances, hype and claiming credit."
Proposition 71 that created CIRM passed by 59 percent of Californians voting in 2004. Consumer Watchdog's Stem Cell Oversight and Accountability Project is working to ensure that California's landmark stem cell research program offers accessible and affordable cures and treatments to the taxpayers who have funded it. The program will sell $3 billion in bonds over a decade to fund stem cell research. Financing charges mean the project, the largest source of stem cell research funding in the world, will cost California taxpayers $6 billion.
Consumer Watchdog, formerly the Foundation for Taxpayer and Consumer Rights, is California's leading non-profit and non-partisan consumer watchdog group. For more information visit us on the web at: http://www.consumerwatchdog.org/.
Consumer Watchdog
CONTACT: John M. Simpson of Consumer Watchdog, +1-310-392-0522, ext.317, cell: +1-310-292-1902
Web Site: http://www.consumerwatchdog.org/
Source: PRNewswire-USNewswire
Related Articles
- Stem Cell Transplantation Research at The Cancer Center at Hackensack University Medical Center Aims to Develop 'Designer' Transplants
- 454 Sequencing at the Forefront of Bone Marrow and Stem Cell Therapy Research
- International Stem Cell Corporation to Provide Corneal Epithelial Cells Differentiated From Its Parthenogenetic Stem Cells for Use in Photorefractive Keratectomy (PRK) FDA Clinical Trials
- National Stem Cell Applies for $1,725,000 Grant From State of Maryland
- Osiris Therapeutics Receives FDA Fast Track Status for Its Crohn's Disease Stem Cell Therapy and Clearance to Start Phase III Clinical Trial
- Cooper and Coriell Pioneer Stem Cell Heart Research; Partnership Changes the Face of Research for Cardiac Care
- Fate of Stanford's New Stem Cell Lines in Limbo As Lawsuit Delays Funds
- New York Blood Center Praises Passage of Stem Cell Therapeutic & Research Act of 2005 Which Will Help Save Lives of Thousands
- Stem Cell Therapy Will Need Watchdogs: Scientists
- Stem Cell Panel Expects to Award Grants
User Comments (0)

RSS Feeds